| Medical and Health Sciences | Lifetime | 720 | CN 10 | 99.97 |
| Biological Sciences | Lifetime | 625 | CN 16 | 99.93 |
| Medical and Health Sciences | 2021-2025 | 74 | CN 7 | 99.98 |
| Biological Sciences | 2021-2025 | 49 | CN 16 | 99.96 |
| Economics and Finance | 2021-2025 | 234 | CN 68 | 99.26 |
| Molecular Biology | Lifetime | 649 | CN 25 | 99.67 |
| Oncology | Lifetime | 261 | CN 6 | 99.58 |
| Cancer Research | Lifetime | 127 | CN 5 | 99.30 |
| Immunology | Lifetime | 210 | CN 3 | 99.51 |
| Epidemiology | Lifetime | 515 | CN 15 | 99.36 |
| Pulmonary and Respiratory Medicine | Lifetime | 460 | CN 8 | 99.39 |
| Surgery | Lifetime | 830 | CN 9 | 99.21 |
| Public, Environmental and Occupational Health | Lifetime | 845 | CN 15 | 98.79 |
| Emergency Medical Services | Lifetime | 266 | CN 3 | 97.47 |
| Medical Genetics | Lifetime | 385 | CN 7 | 96.72 |
| Clinical Neurology | Lifetime | 648 | CN 11 | 96.80 |
| Pathology and Forensic Medicine | Lifetime | 754 | CN 18 | 96.47 |
| Transportation | Lifetime | 894 | CN 142 | 92.85 |
| Hematology | Lifetime | 637 | CN 6 | 94.98 |
| Nephrology | Lifetime | 495 | CN 17 | 94.87 |
| Library and Information Sciences | Lifetime | 372 | CN 5 | 91.17 |
| Anesthesiology and Pain Medicine | Lifetime | 469 | CN 7 | 89.83 |
| Reproductive Medicine | Lifetime | 824 | CN 13 | 89.61 |
| Biotechnology | Lifetime | 631 | CN 41 | 88.02 |
| Hepatology | Lifetime | 670 | CN 43 | 89.35 |
| Complementary and Alternative Medicine | Lifetime | 991 | CN 119 | 81.59 |
| Radiation Physics | Lifetime | 990 | CN 33 | 79.85 |
| Parasitology | Lifetime | 769 | CN 21 | 76.43 |
| Cancer Research | 2021-2025 | 7 | CN 3 | 99.78 |
| Oncology | 2021-2025 | 37 | CN 5 | 99.81 |
| Surgery | 2021-2025 | 77 | CN 4 | 99.55 |
| Molecular Biology | 2021-2025 | 90 | CN 41 | 99.65 |
| Immunology | 2021-2025 | 24 | CN 4 | 99.48 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 70 | CN 9 | 99.65 |
| Public, Environmental and Occupational Health | 2021-2025 | 89 | CN 5 | 99.26 |
| Epidemiology | 2021-2025 | 119 | CN 14 | 99.23 |
| Econometrics and Quantitative Economics | 2021-2025 | 221 | CN 64 | 99.06 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 207 | CN 22 | 96.03 |
| Anesthesiology and Pain Medicine | 2021-2025 | 38 | CN 2 | 94.47 |
| Pathology and Forensic Medicine | 2021-2025 | 199 | CN 24 | 94.44 |
| Medical Genetics | 2021-2025 | 154 | CN 4 | 93.94 |
| Clinical Neurology | 2021-2025 | 261 | CN 11 | 92.45 |
| Nephrology | 2021-2025 | 162 | CN 14 | 92.61 |
| General Health Professions | 2021-2025 | 967 | CN 24 | 91.84 |
| Hematology | 2021-2025 | 220 | CN 4 | 91.64 |
| Reproductive Medicine | 2021-2025 | 207 | CN 8 | 90.15 |
| Nutrition and Dietetics | 2021-2025 | 280 | CN 88 | 89.44 |
| Medical Physiology | 2021-2025 | 744 | CN 54 | 88.10 |
| Genetics | 2021-2025 | 514 | CN 41 | 85.50 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 562 | CN 22 | 79.20 |
| Hepatology | 2021-2025 | 319 | CN 27 | 76.36 |
| Biotechnology | 2021-2025 | 163 | CN 33 | 57.47 |
| Cancer-related molecular mechanisms research | Lifetime | 22 | CN 7 | 99.80 |
| RNA modifications and cancer | Lifetime | 143 | CN 9 | 99.56 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 144 | CN 5 | 99.63 |
| Circular RNAs in diseases | Lifetime | 74 | CN 38 | 99.26 |
| Immune Cell Function and Interaction | Lifetime | 294 | CN 6 | 99.61 |
| Immunotherapy and Immune Responses | Lifetime | 257 | CN 7 | 99.56 |
| MicroRNA in disease regulation | Lifetime | 226 | CN 77 | 99.08 |
| Epigenetics and DNA Methylation | Lifetime | 262 | CN 12 | 99.21 |
| Ferroptosis and cancer prognosis | Lifetime | 87 | CN 31 | 98.56 |
| T-cell and B-cell Immunology | Lifetime | 325 | CN 4 | 99.35 |
| Molecular Biology Techniques and Applications | Lifetime | 158 | CN 5 | 98.47 |
| Cancer-related gene regulation | Lifetime | 238 | CN 20 | 98.53 |
| CAR-T cell therapy research | Lifetime | 365 | CN 5 | 98.91 |
| Acute Ischemic Stroke Management | Lifetime | 396 | CN 15 | 98.78 |
| Immune cells in cancer | Lifetime | 297 | CN 28 | 98.30 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 112 | CN 13 | 96.84 |
| Central Venous Catheters and Hemodialysis | Lifetime | 248 | CN 5 | 98.12 |
| Cancer Diagnosis and Treatment | Lifetime | 440 | CN 4 | 97.81 |
| Lung Cancer Treatments and Mutations | Lifetime | 811 | CN 51 | 98.36 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 873 | CN 28 | 98.16 |
| Mesenchymal stem cell research | Lifetime | 486 | CN 58 | 97.67 |
| Prostate Cancer Treatment and Research | Lifetime | 598 | CN 7 | 98.35 |
| RNA Research and Splicing | Lifetime | 996 | CN 35 | 97.50 |
| Lung Cancer Research Studies | Lifetime | 613 | CN 29 | 97.88 |
| Cancer Research and Treatments | Lifetime | 748 | CN 42 | 96.54 |
| Galectins and Cancer Biology | Lifetime | 387 | CN 7 | 96.24 |
| Gene expression and cancer classification | Lifetime | 380 | CN 36 | 96.74 |
| Neuroendocrine Tumor Research Advances | Lifetime | 971 | CN 10 | 97.11 |
| Esophageal Cancer Research and Treatment | Lifetime | 895 | CN 43 | 95.96 |
| Cancer Mechanisms and Therapy | Lifetime | 548 | CN 94 | 94.82 |
| Acute Kidney Injury Research | Lifetime | 485 | CN 26 | 95.53 |
| PARP inhibition in cancer therapy | Lifetime | 562 | CN 18 | 94.04 |
| Retinoids in leukemia and cellular processes | Lifetime | 840 | CN 34 | 94.12 |
| Breast Lesions and Carcinomas | Lifetime | 860 | CN 12 | 94.97 |
| Chemokine receptors and signaling | Lifetime | 637 | CN 25 | 92.41 |
| Phagocytosis and Immune Regulation | Lifetime | 621 | CN 42 | 92.09 |
| Nuclear Receptors and Signaling | Lifetime | 694 | CN 42 | 91.64 |
| Gestational Trophoblastic Disease Studies | Lifetime | 890 | CN 45 | 79.76 |
| Cancer-related molecular mechanisms research | 2021-2025 | 9 | CN 6 | 99.90 |
| RNA modifications and cancer | 2021-2025 | 27 | CN 17 | 99.66 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 45 | CN 4 | 99.80 |
| Immunotherapy and Immune Responses | 2021-2025 | 26 | CN 5 | 99.50 |
| Immune Cell Function and Interaction | 2021-2025 | 73 | CN 18 | 98.76 |
| Immune cells in cancer | 2021-2025 | 64 | CN 37 | 98.23 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 145 | CN 14 | 98.51 |
| Epigenetics and DNA Methylation | 2021-2025 | 138 | CN 62 | 97.05 |
| RNA Research and Splicing | 2021-2025 | 95 | CN 27 | 96.88 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 267 | CN 77 | 97.69 |
| Ferroptosis and cancer prognosis | 2021-2025 | 183 | CN 144 | 97.01 |
| MicroRNA in disease regulation | 2021-2025 | 233 | CN 148 | 97.07 |
| Prostate Cancer Treatment and Research | 2021-2025 | 171 | CN 5 | 98.16 |
| Circular RNAs in diseases | 2021-2025 | 116 | CN 84 | 97.10 |
| Lung Cancer Research Studies | 2021-2025 | 195 | CN 34 | 97.50 |
| T-cell and B-cell Immunology | 2021-2025 | 171 | CN 16 | 94.79 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 414 | CN 74 | 96.64 |
| Anesthesia and Sedative Agents | 2021-2025 | 92 | CN 12 | 95.05 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 179 | CN 9 | 95.75 |
| Cancer Diagnosis and Treatment | 2021-2025 | 114 | CN 7 | 92.09 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 540 | CN 99 | 96.60 |
| Phagocytosis and Immune Regulation | 2021-2025 | 64 | CN 24 | 91.65 |
| Cervical Cancer and HPV Research | 2021-2025 | 351 | CN 32 | 93.35 |
| Hepatitis B Virus Studies | 2021-2025 | 394 | CN 69 | 93.47 |
| Peptidase Inhibition and Analysis | 2021-2025 | 453 | CN 123 | 91.93 |
| Viral-associated cancers and disorders | 2021-2025 | 207 | CN 32 | 92.60 |
| Acute Myeloid Leukemia Research | 2021-2025 | 696 | CN 46 | 94.19 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 579 | CN 49 | 93.48 |
| Acute Kidney Injury Research | 2021-2025 | 234 | CN 48 | 91.07 |
| Cancer Cells and Metastasis | 2021-2025 | 524 | CN 108 | 88.56 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 547 | CN 155 | 91.59 |
| PARP inhibition in cancer therapy | 2021-2025 | 291 | CN 20 | 91.37 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 587 | CN 39 | 91.71 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 721 | CN 86 | 91.53 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 673 | CN 154 | 90.67 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 620 | CN 42 | 91.68 |
| interferon and immune responses | 2021-2025 | 473 | CN 261 | 87.11 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 313 | CN 48 | 87.81 |
| Genetic factors in colorectal cancer | 2021-2025 | 708 | CN 59 | 89.07 |
| Dialysis and Renal Disease Management | 2021-2025 | 578 | CN 46 | 90.86 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 313 | CN 132 | 85.55 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 107 | CN 17 | 85.31 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 287 | CN 92 | 86.09 |
| Breast Cancer Treatment Studies | 2021-2025 | 974 | CN 84 | 90.12 |
| Mycobacterium research and diagnosis | 2021-2025 | 591 | CN 92 | 86.98 |
| Cancer-related gene regulation | 2021-2025 | 577 | CN 398 | 82.83 |
| Breast Lesions and Carcinomas | 2021-2025 | 366 | CN 25 | 85.50 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 780 | CN 23 | 86.71 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 507 | CN 25 | 83.58 |
| Congenital Diaphragmatic Hernia Studies | 2021-2025 | 626 | CN 42 | 83.33 |
| Urinary and Genital Oncology Studies | 2021-2025 | 607 | CN 32 | 86.48 |
| Prenatal Screening and Diagnostics | 2021-2025 | 720 | CN 155 | 83.86 |
| Airway Management and Intubation Techniques | 2021-2025 | 598 | CN 31 | 81.34 |
| Nausea and vomiting management | 2021-2025 | 255 | CN 53 | 80.39 |
| Cancer-related cognitive impairment studies | 2021-2025 | 348 | CN 41 | 80.87 |
| Family Support in Illness | 2021-2025 | 669 | CN 54 | 80.02 |
| DNA Repair Mechanisms | 2021-2025 | 940 | CN 123 | 78.80 |
| Neonatal and fetal brain pathology | 2021-2025 | 982 | CN 63 | 79.80 |
| Cancer Mechanisms and Therapy | 2021-2025 | 834 | CN 373 | 73.66 |
| Vitamin D Research Studies | 2021-2025 | 934 | CN 85 | 72.94 |
| Kruppel-like factors research | 2021-2025 | 296 | CN 105 | 71.44 |
| Vitamin C and Antioxidants Research | 2021-2025 | 389 | CN 23 | 71.04 |
| Cell Adhesion Molecules Research | 2021-2025 | 887 | CN 122 | 69.49 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 952 | CN 239 | 69.18 |
| Nuts composition and effects | 2021-2025 | 391 | CN 90 | 69.09 |
| Family Caregiving in Mental Illness | 2021-2025 | 476 | CN 35 | 66.47 |
| Chromatin Remodeling and Cancer | 2021-2025 | 576 | CN 71 | 64.22 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 477 | CN 83 | 53.15 |